104.18  -1.083 (-1.03%)		10-30 15:41
Open: 105.03 High: 105.27 Volume: 12,322		Pre. Close: 105.2625 Low: 103.6597 Market Cap: 42(M)

Short term
Mid term
Targets	6-month :	125.04	1-year :	146.04
Resists	First :	107.05	Second :	125.04
Pivot price	103.47
Supports	First :	102.37	Second :	99.48
MAs	MA(5) :	104.41	MA(20) :	103.21
	MA(100) :	100.85	MA(250) :	89.66
MACD	MACD :	0.1	Signal :	-0.1
%K %D	K(14,3) :	76	D(3) :	75.1
RSI	RSI(14): 50.3
52-week	High :	110.05	Low :	72.8

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ BBP ] has closed below upper band by 43.8%. Bollinger Bands are 24.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	105.32 - 106.02	106.02 - 106.61
Low:	102.29 - 102.99	102.99 - 103.56
Close:	102.9 - 104.03	104.03 - 104.96

The Virtus Biotech ETF seeks to replicate the overall financial performance, encompassing both price appreciation and income generation, of the LifeSci Biotechnology Products Index, prior to any deductions for fees and expenses. This index specifically comprises biotechnology companies that have received approval from the FDA for at least one drug therapy. Furthermore, the fund underwent a name change on February 27, transitioning from Virtus LifeSci Biotech Products ETF to its current designation.

Wed, 28 Oct 2026
ETFs That You May Consider Amid a Strengthening Biotech Outlook - TradingView

Mon, 21 Sep 2026
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate - TradingView

Thu, 20 Aug 2026
BBP: The Biotech ETF That Filters For FDA-Approved Drugs (NYSEARCA:BBP) - Seeking Alpha

Wed, 27 May 2026
5 Small-cap Biotech ETFs to Watch in 2026 - Investing News Network

Fri, 16 Jun 2023
Virtus LifeSci Biotech Products ETF Review and Aggregate Rating (BBP) $BBP - MarketBeat

Tue, 28 Feb 2023
BBP Top Holdings List & Exposure (Virtus LifeSci Biotech Products ETF) - MarketBeat

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: AMEX
Sector: Financial Services
Industry: Asset Management
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.